DNLI — Denali Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $2.20bn
- $1.16bn
- $330.53m
- 56
- 25
- 49
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 415 | 1,470 | 865 | 1,336 | 1,035 |
Net Total Receivables | — | 5.67 | 1.23 | 0 | — |
Prepaid Expenses | |||||
Total Current Assets | 430 | 1,496 | 897 | 1,372 | 1,064 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 80.7 | 73.5 | 69.6 | 74.5 | 71.6 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 553 | 1,604 | 1,404 | 1,460 | 1,154 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 45.3 | 71.7 | 378 | 364 | 78 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 158 | 454 | 442 | 418 | 123 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 395 | 1,151 | 962 | 1,042 | 1,031 |
Total Liabilities & Shareholders' Equity | 553 | 1,604 | 1,404 | 1,460 | 1,154 |
Total Common Shares Outstanding |